DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has contracted with two employers to provide its highly personalized digital therapeutic beginning in the first quarter of 2022.
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 15, 2021, DarioHealth Corp. (NASDAQ:DRIO) announced its third quarter 2021 operational and financial results and filed its Form 10-Q . Dario hosted a conference call the following morning to discuss results in further detail. Dario’s growth is accelerating with
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter of 2021 and provided a corporate and commercial update.